B Cell Receptors and Surface Markers
Native-like Structure. Bioactive Performance. Reliable Results.
Conigen’s recombinant B cell receptors (BCRs), including CD19 mimic native conformations and antigen responsiveness, supporting discovery in immunology, oncology, and antibody engineering.
The BCR complex enables antigen recognition and signaling in B cells, facilitating activation, differentiation, and memory formation. CD19 and CD27, Type I transmembrane proteins, are important markers on B cells involved in B cell function. CD19 is important for B cell development and acts as a co-receptor with the BCR to enhance signaling and activation. Dysregulation or overexpression of these molecules contributes to immune disorders and B-cell malignancies.
Conigen’s recombinant proteins enable the study of receptor clustering, epitope recognition, and therapeutic antibody interactions in native-like formats.
Available B Cell Receptors
| Product | Tag | Species | Product Code | Product Details |
|---|---|---|---|---|
| CSP-25291-01 | |||
| CSP-24125-03 | |||
| CSP-24125-01 | |||
| CSP-124-01 |
CD19 FAQs
What are the benefits of using dimerized CD19 in my workflow?
Conigen’s dimerized proteins are engineered to replicate the native, cell-surface conformation of proteins more closely than monomeric ectodomains.
In practice, dimerized CD19 typically delivers:
- Higher binding potency
- Improved assay sensitivity
- Wider assay windows
Which tags and labels are available for CD19 proteins?
Conigen offers CD19 proteins in multiple tag formats, including His-tagged and His-Avi-tagged and biotinylated catalog dimers.
Additional tags such as Fc, Flag, HA, or Myc can be provided through custom expression to match your assay or conjugation needs.
What species are your recombinant proteins derived from?
Our recombinant proteins are produced using gene sequences originating from a variety of species including human, mouse and non-human primates. All proteins are expressed in mammalian cells to ensure consistent and relevant post-translational modifications.
How is the binding affinity of CD19 proteins validated?
Each CD19 protein dimer is bioactivity-verified through antibody binding ELISA, with QC-reported EC50 ranges demonstrating potent, specific recognition by anti-CD19 monoclonal antibodies. SPR/BLI workflows are supported as downstream affinity applications.
Can your CD19 proteins be used to detect CAR-T cells via flow cytometry?
Our CD19 recombinant proteins have been used by customers in research applications, including flow cytometry-based assays to study CAR-T cells. However, assay performance and suitability depend on the specific experimental design and conditions. We recommend that customers validate the protein for their intended use.
Can CD19 proteins be customized for my application?
Yes. CD19 proteins can be customized through Conigen’s CSP™ platform.
What is the lead time for ordering CD19 proteins?
Lead time varies by format and scale. Catalog CD19 can be ordered directly and will ship within 2-3 business days of sales order receipt.
Custom CD19 and larger orders will follow a defined project workflow, but will generally be shipped 4-6 weeks following request. Contact us for a precise delivery estimate.
How can I place an order or request a custom CD19 protein?
You can order CD19 proteins directly through the product page using Add to Cart or Add to Quote. For purchasing support or custom CD19 formats (alternate tags, variants, or assay-specific constructs), email [email protected] or submit a request through our Custom Project form.
Can CD19 be used as an immunogen?
Recombinant CD19 proteins have been used by customers in research settings as immunogens for antibody development. However, immunogenicity and antibody responses depend on multiple factors, including protein format, host species, and immunization protocol. Customers should perform their own validation to determine suitability for their intended application.
Can’t Find the Product You Need?
Spotlight: CD19
Bioactive Performance
CD19 is a coreceptor in the BCR complex and a central marker for B-cell targeting in immunotherapy. Although CD19 doesn’t form a dimer under physiological conditions, the CD19 overexpression and potential clustering in cancer cells enhance pro-survival signaling while posing challenges to immunotherapies. Targeting the overexpressed clustering CD19 may improve the therapeutic precision and overcome resistance.
Mouse CD19 protein dimer, His Tag (CSP-124-01) potently binds to CD19 specific monoclonal antibody (mAb) as measured by ELISA. The CD19 protein dimer (0.2 μg/ml) was coated on 96-well microtiter plates and detected by serial dilutions of anti-mouse CD19 mAb.
This recombinant protein supports structural and therapeutic research aimed at overcoming antigen escape and resistance in B-cell malignancies.